帕金森病预防试验应测试什么?老药新用、低风险与基因靶向药物
本文阐述帕金森病预防试验的药物选择原则,聚焦于验证概念的机会,以期为这一新兴领域建立方法学基础。文章描述了相对低风险的候选药物(如沙丁胺醇、氨溴索、咖啡因、布洛芬),适用于从致病性LRRK2或GBA基因变异携带者到前驱期帕金森病和α-突触核蛋白病患者等特定高危人群,并回顾了目前针对临床显性帕金森病开发的基因靶向方法在未來预防试验中的潜力。
要点
- 帕金森病预防试验应聚焦于验证概念的机会,为这一新兴领域建立方法学基础。
- 相对低风险的候选药物包括沙丁胺醇、氨溴索、咖啡因和布洛芬,适用于特定高危人群。
- 基因靶向方法目前针对临床显性帕金森病开发,未来可能用于预防试验。
核心结论
- 尽管大量疾病修饰试验有理据支持,但尚无治疗能令人信服地证明延缓帕金森病进展,预防试验需聚焦于验证概念的机会以建立方法学基础。
研究设计与样本
- 本文为综述,概述帕金森病预防试验的药物选择原则,并回顾相关候选药物与基因靶向方法。
主要发现
- 相对低风险的候选药物包括沙丁胺醇、氨溴索、咖啡因和布洛芬,适用于从致病性LRRK2或GBA基因变异携带者到前驱期帕金森病和α-突触核蛋白病患者等特定高危人群。
- 基因靶向方法目前针对临床显性帕金森病开发,未来可能用于预防试验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the sound epidemiologic and basic science rationales underpinning numerous "disease modification" trials in manifest Parkinson disease (PD), none has convincingly demonstrated that a treatment slows progression. Rapidly expanding knowledge of the genetic determinants and prodromal features of PD now allows realistic planning of prevention trials with initiation of putatively neuroprotective therapies earlier in the disease. In this article, we outline the principles of drug selection for PD prevention trials, focused on proof-of-concept opportunities that will help establish a methodological foundation for this fledgling field. We describe prototypical, relatively low-risk drug candidates for such trials (e.g., albuterol, ambroxol, caffeine, ibuprofen), tailored to specific at-risk populations ranging from pathogenic LRRK2 or GBA gene variant carriers to those defined by prodromal PD and α-synucleinopathy. Finally, we review gene-targeted approaches currently in development targeting clinically manifest PD for their potential in future prevention trials.
引用
- Crotty GF, Schwarzschild MA. What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs. Neurology. 2022. PMID: 35970592. doi:10.1212/WNL.0000000000200238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。